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AROS Is a Significant Biomarker for Tumor Aggressiveness
in Non-cirrhotic Hepatocellular Carcinoma
Despite a low risk of liver failure and preserved liver function, non-cirrhotic hepatocellular 
carcinoma (HCC) has a poor prognosis. In the current study, we evaluated an active 
regulator of SIRT1 (AROS) as a prognostic biomarker in non-cirrhotic HCC. mRNA levels of 
AROS were measured in tumor and non-tumor tissues obtained from 283 non-cirrhotic 
HCC patients. AROS expression was exclusively up-regulated in recurrent tissues from the 
non-cirrhotic HCC patients (P = 0.015) and also in tumor tissues irrespective of tumor 
stage (P < 0.001) or BCLC stage (P < 0.001). High mRNA levels of AROS were statistically 
significantly associated with tumor stage (P < 0.001), BCLC stage (P = 0.007), alpha 
fetoprotein (AFP) level (P = 0.013), microvascular invasion (P = 0.001), tumor size  
(P = 0.036), and portal vein invasion (P = 0.005). Kaplan-Meir curve analysis demonstrated 
that HCC patients with higher AROS levels had shorter disease-free survival (DFS) in both 
the short-term (P < 0.001) and long-term (P = 0.005) compared to those with low AROS. 
Cox regression analysis demonstrated that AROS is a significant predictor for DFS along 
with large tumor size, tumor multiplicity, vascular invasion, and poor tumor differentiation, 
which are the known prognostic factors. In conclusion, AROS is a significant biomarker for 
tumor aggressiveness in non-cirrhotic hepatocellular carcinoma.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is the most prevalent type of primary liver cancer 
and one of the most fatal solid tumors in the world (1). Most HCC are accompanied by 
liver cirrhosis, which is caused by multiple extrahepatic factors including alcohol, hep-
atitis viruses, and fatty liver disease (2-5). During the progression of cirrhosis, the liver 
undergoes fibrosis, scarring, and hepatocellular regeneration, resulting in the accumu-
lation of aberrant cells with genetic mutations causally associated with liver malignancy 
(6, 7).
 Non-cirrhotic HCC comprises a relatively small proportion (10%-30%) of HCC cases 
(8). Since non-cirrhotic HCC has a low risk of liver failure, it is eligible for hepatic resec-
tion and has a generally good prognosis compared to cirrhotic HCC (9-12). In contrast, 
only a small proportion of cirrhotic HCC patients are amenable to hepatic resection. 
The pathology of non-cirrhotic HCC is peculiarly characterized by a large tumor size 
due to delayed diagnosis, resulting in a more aggressive clinical phenotype at the time 
of diagnosis. Additionally, fibrolamellar HCC (FL-HCC) is exclusively observed in non-
cirrhotics (7). Despite their prognostic importance and rare pathobiological attributes, 
little is known about the molecular characteristics of non-cirrhotic HCC compared to 
cirrhotic HCC. While cirrhosis plays certain roles to develop hepatocellular carcinoma 
in cirrhotic-HCC, in non-cirrhotic HCC, the molecular characteristics are more impor-
tant for hepatocarcinogenesis in the absence of cirrhosis.
 Active regulator of SIRT1 (AROS) is a ribosomal protein S19 (RPS19)-binding factor 
also known as RPS19BP1. In cancer, SIRT1 plays dual roles as a tumor promoter or sup-
pressor through its extensive deacetylase activity toward many kinds of proteins such 
as p53, HSF1, FOXO3a, STAT3, and mTOR (13, 14). In accordance with the multiple 
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roles of SIRT1, its interacting partner AROS may have diverse 
functions in cancer through a SIRT1-dependent pathway. AROS 
is ubiquitously expressed in various mouse (15) and human or-
gans but is overexpressed in cancer cell lines (16). Furthermore, 
AROS plays a role as an activator of SIRT1, which is frequently 
expressed at later stages of HCC (17, 18). However, the expres-
sion of AROS and its clinical implications in HCC are not well 
explored and thus need to be investigated.
 The aim of this study was to evaluate the underlying molecu-
lar characteristics of non-cirrhotic HCC. Specifically, we evalu-
ated, for the first time, the expression of AROS and its clinical 
implications as a prognostic biomarker in non-cirrhotic HCC.
MATERIALS AND METHODS
Patients and tissues 
HCC tissues and non-tumoral hepatic tissues were obtained 
with informed consent from 283 patients without cirrhosis who 
had undergone curative hepatectomy for primary HCC between 
1995 and 2007 at Ajou University Medical Center, Samsung Med-
ical Center, Keimyung University Dongsan Medical Center, and 
Hanyang University Medical Center in Korea. Tissue analysis 
and statistical analysis were performed at Cbs Bioscience Inc. 
The study protocol was approved by the respective Institutional 
Review Boards. All patients had adequate liver function reserve 
(class A = 277, class B: 6) and had survived for at least 2 months 
after hepatectomy. Clinicopathological results and recurrence 
or death was obtained from the medical records of patients in 
each center and analyzed retrospectively. Non-cirrhotic HCC 
was defined by the lack of bridging fibrosis in background non-
neoplastic liver tissues. We defined recurrence state as evidence 
of an overt new growing tumor mass in the remaining liver or 
as distant metastasis in radiologic studies including computed 
tomography or magnetic resonance imaging. In the current 
study, patients who had received treatment prior to surgery 
such as transcatheter arterial chemoembolization or radiofre-
quency ablation were excluded. Immediately after hepatecto-
my, fresh tumors and background livers were partly snap-fro-
zen in liquid nitrogen and stored at -80°C for RT-PCR analysis. 
The tumor grading followed the criteria proposed by Edmond-
son and Steiner (I, well differentiated; II, moderately differenti-
ated; III, poorly differentiated; and IV, undifferentiated). The 
conventional tumor-node-metastasis system outlined in the 
Cancer Staging Manual (6th edition) published by the American 
Joint Committee on Cancer was used for tumor staging. 
RNA extraction and cDNA synthesis 
Total RNA was extracted from frozen HCC and non-tumoral 
hepatic tissues using an RNeasy minikit (Qiagen, Hilden, Ger-
many) according to the manufacturer’s protocol. Additionally, 
DNase I treatment was routinely included in the extraction step. 
The total RNA integrity was evaluated by a Bioanalyzer 2,100 
(Agilent Technologies, Santa Clara, CA, USA). Four μg of total 
RNA was incubated with 2 μL of 10 μM oligo d (T)18 primer 
(Genotech, Daejeon, Korea) at 70°C for 7 min and cooled on ice 
for 5 min. After adding the reverse transcriptase enzyme-con-
taining master mix to the annealed total RNA sample, the reac-
tion was incubated for 90 min at 42°C followed by heat inactiva-
tion of the enzyme at 80°C for 10 min. The cDNA samples were 
adjusted to a final volume of 400 μL by adding diethylpyrocar-
bonate (DEPC)-treated water.
Quantitative real-time PCR 
Real-time PCR was performed as described previously (19). Us-
ing Applied Biosystems Prism 7900HT (Applied Biosystems, 
Foster City, CA, USA), real-time PCR was performed in a total 
volume of 10 μL with the amplification steps described below: 
an initial activation step at 95°C for 10 min which was followed 
by 45 cycles of denaturation at 95°C for 15 sec and elongation at 
60°C for 1 min. The primer and probe sequences were designed 
using Primer Express 3.0 software (Applied Biosystems), and all 
probes were labeled with FAM at the 5´ end and with TAMRA at 
the 3´ end. The sequence of primers and probes are displayed 
in Table S1. AROS was amplified and quantified using the for-
ward primer, 5´-CGGAAGACGAAGGCAATTCA-3´, the reverse 
primer 5´-GCCGACTTGGGCACCTTT-3´, and the probe 5´-CC 
AGAAACTGCGGAACTCGGCCA-3´. The mRNA levels for AROS 
were measured (the threshold cycle, Ct) in triplicate and then 
normalized relative to a set of reference genes (beta-2-micro-
globulin [B2M], GAPDH, hydroxymethylbilane synthase [HMBS], 
hypoxanthine phosphoribosyltransferase 1 [HPRT1], and suc-
cinate dehydrogenase complex, subunit A, flavoprotein [SDHA]) 
with subtraction of the average expression for the five reference 
genes as an internal control (20). Using the difference between 
target gene Ct and average Ct of the reference genes (∆Ct values), 
the mRNA levels were calculated as 2-∆Ct.
Statistical analysis
Clinicopathologic characteristics of the HCC patients were eval-
uated using a chi square test and Fisher’s exact test. The gene 
expression data were normalized by means of a log2 transform. 
After transformation, the results for each gene were centered 
and scaled to an average of 0 and SD of 1. Genes achieving P 
values of < 0.05 in the Univariate Cox analyses were then input 
as potential predictors of patient risk. The classification accura-
cy was measured by the area under the curve (AUC) of the re-
ceiver-operator curves (ROC). Cumulative disease free survival 
(DFS) was analyzed using Kaplan-Meier survival curves. The 
statistical significance in different survival curves between the 
AROS-low group and the AROS-high group was examined by a 
log-rank test. Significant differences between gene expression 
levels for HCC and non-cancerous tissues were evaluated by a 
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Student’s t-test. A two-tailed P value test was used, with a P val-
ue of < 0.05 considered statistically significant. All statistical 
analyses were conducted using the open source statistical pro-
gramming environment R.
Ethics statements
This study protocol was approved by the institutional review 
board of Keimyung University Dongsan Medical Center (IRB 
No. 11-54), Ajou University Medical Center (AJIRB-GEN-KSP- 
09-278), Samsung Medical Center (2009-01-030-008), and Han-
yang University Medical Center (HYG-09-11). Informed consent 
was waived by the board of each institution.
 
RESULTS
Clinicopathologic characteristics
A total of 283 patients were enrolled, 219 men and 64 women. 
The age ranged between 20 and 76 (mean of 52.0). The rates of 
hepatitis B and C were 63.6% (n = 180) and 8.8% (n = 25) respec-
tively. Mean tumor size was 6.12 (range 1-20) cm and 68 patients 
(24.0%) had multiple tumors. The distribution of BCLC stages 
(A/B/C) were 45.2% (n = 128), 42.0% (n = 119) and 12.7% (n =  
36), respectively. Patients at BCLC C stage consisted of 35 pati-
ents with portal vein invasion and 1 patient with impaired phys-
ical status (Table S2). 
AROS is overexpressed in tumor tissues compared to non-
tumor tissues in non-cirrhotic HCC
mRNA expression of AROS was examined in frozen tissues de-
rived from non-cirrhotic HCC using real-time RT-PCR. mRNA 
levels of AROS were measured in triplicate and then normal-
ized relative to the expression of 5 reference genes (B2M, GAP-
DH, HMBS, HPRT1, and SDHA) as an internal control. 
 AROS mRNA was significantly higher in tumor tissues than 
in non-tumor tissues (0.2219 vs. 0.3706; mean copy number ra-
tio, P < 0.001; Fig. 1A). In non-cirrhotic HCC, AROS expression 
was significantly up-regulated in tumors compared to non-tu-
mors at each tumor stage and its average expression in tumors 
Fig. 1. (A) AROS expression in HCC (T) compared to surrounding non-tumoral tissues (NT) in LC and NonLC. Both cirrhotic and non-cirrhotic tumors expressed significantly high-
er levels of AROS (P < 0.0001). (B) AROS expression in non-cirrhotic HCC (T) compared to surrounding non-tumoral tissues (NT) in total and across stages. mRNA levels of AROS 
were significantly up-regulated in tumors compared to non-tumors irrespective of tumor stages and BCLC stages. (C) Comparative analysis of AROS mRNA levels in HCC tissues 
with (recu) or without postoperative recurrence (non-recu) within 2 yr. AROS expression was higher in recurrent tumors than in non-recurrent tumors exclusively in NonLC, but 
not LC.
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increased along with the stages (stage I: 0.2331 vs. 0.3089; stage 
II: 0.2198 vs. 0.4021; stage III_IV: 0.2110 vs. 0.4187). Higher ex-
pression of AROS in tumors was also observed in all BCLC stag-
es (stage A: 0.2313 vs. 0.3509; stage B: 0.2165 vs. 0.3830; stage C: 
0.2036 vs. 0.3991) and differences between tumors and non-tu-
mors were statistically significant (P < 0.001; Fig. 1B).
 To examine the potential relevance of AROS expression with 
non-cirrhotic HCC prognosis, AROS expression was analyzed 
according to the presence of post-operative recurrence. mRNA 
levels of AROS were significantly higher in HCC patients that 
experienced recurrence within 2 yr of hepatic resection than in 
those who did not (0.3436 vs. 0.4039; mean copy number ratio, 
P = 0.015; Fig. 1C). Furthermore, the gene expression pattern 
showing up-regulation of AROS in recurrent tissues remained 
significant in tissues at the 5-yr follow-up time point (0.3381 vs. 
0.3981, P = 0.014; Fig. S1).
Non-cirrhotic HCC patients with high expression of AROS 
have a shorter disease-free survival
To assess the prognostic significance of AROS expression in the 
short term, ROC curves for DFS within 2 yr were constructed. 
The cutoff values for AROS mRNA levels (θ = 1.075; 35.3% sen-
sitivity, 82.2% specificity, and 62.2% accuracy) were determined 
based on the highest accuracy that discriminated between pa-
tients with good prognosis and poor prognosis from the ROC 
curves for DFS. The area under the curve (AUC) for the ROC 
curve showing the prediction of DFS within 2 yr by AROS mRNA 
level was 0.576 (Fig. 2A). The prognostic significance of AROS 
expression was further analyzed using the Kaplan-Meier meth-
od. At the 2-yr follow-up, 35.4% of the patients with low AROS 
expression experienced recurrence, whereas 57.8% of the pa-
tients with high AROS expression recurred (P < 0.001). During 
2 yr of follow-up, HCC patients with high levels of AROS dis-
played significantly shorter DFS time than those with low AROS 
levels (P < 0.001; Fig. 2B).
 Additionally, the long-term (5 yr) prognostic value of AROS 
was evaluated using the same cutoff value for AROS as for the 
2-yr prognosis. The AUC value of the ROC curve used to stratify 
patients with shorter DFS by AROS levels was 0.575. The cutoff 
values for AROS mRNA level were the same as the values cho-
sen for the short-term prognosis. The sensitivity, specificity, and 
accuracy were 30.2%, 81.5%, and 52.7%, respectively (Fig. S2A). 
At the time point of 5 yr, the KM plot indicated that non-cirrhot-
ic HCC patients with high AROS mRNA levels had a significant-
ly shorter DFS time (P = 0.005; Fig. S2B).
 However, in cirrhotic HCC, there was no significant differ-
ence in prognosis (DFS) between high and low AROS group 
(Fig. S3).
High mRNA levels of AROS are associated with tumor 
stage, BCLC stage, AFP level, vascular invasion, tumor 
size, and portal vein invasion in non-cirrhotic HCC
For a better understanding of the significance of AROS expres-
sion in non-cirrhotic HCC, the correlations between AROS ex-
pression and clinicopathological characteristics were analyzed 
by a chi-square and Fisher’s exact tests (Table 1). According to 
the cutoff values of AROS levels determined by ROC curve anal-
ysis in Fig. 2, the patients were classified as two groups of AROS-
high and AROS-low. High AROS expression was significantly 
correlated with tumor stage (P < 0.001), BCLC stage (P = 0.007), 
high α-fetoprotein (AFP) level (P = 0.013), vascular invasion 
(P = 0.001), large tumor size (P = 0.036), and portal vein inva-
sion (P = 0.005). However, on multivariate analysis with binary 
logistic regression, there were no independent factors related to 
high AROS expression. 
mRNA level of AROS is associated with both short- and 
long-term prognosis in non-cirrhotic HCC
A univariate Cox regression analysis was used to identify impor-
tant prognostic factors for DFS (Table 2). For the non-cirrhotic 
Fig. 2. Non-cirrhotic HCC patients with high levels of AROS expression have a shorter DFS for 2 yr. Kaplan-Meier curves for the DFS of patients who showed high expression 
and low expression of AROS. (A) AUC value of AROS expression at prediction of DFS was 0.576. (B) The AROS-high group showed a significantly shorter DFS time than the 
AROS-low group for 2 yr (P < 0.001). Thin lines, patients expressed higher levels of AROS (n = 71); broken lines, patients expressed lower levels of AROS (n = 212).
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HCCs analyzed by RT-PCR, a high AROS mRNA level was iden-
tified as one of the important risk factors for 2-yr DFS. In the 
same manner, the prognostic significance of AROS levels and 
clinicopathological variables was further evaluated for long-
term (5-yr) DFS. Higher expression of AROS mRNA (P = 0.005) 
was also significantly associated with 5 yr DFS. However, in mul-
tivariate analysis, AROS mRNA level was not a significant risk 
factor (P = 0.080; Table 2, Table S3).
DISCUSSION
Non-cirrhotic HCC is well known to have specific macroscopic 
features including a single and large tumor mass due to both 
delayed diagnosis and a lack of research on screening and prog-
nostic factors (3, 8, 21, 22). We consistently observed a consid-
erably higher proportion of single tumors than multiple tumors 
(Table 2). Additionally, patients with tumor sizes over 5 cm com-
prised about half of all patients. These versatile characteristics 
of non-cirrhotic HCC often worsen the prognosis for non-cir-
rhotics and increase the difficulty of treating non-cirrhotic HCC. 
In the current study, a specific biomarker, AROS (RPS19BP1), 
was identified for the prediction of non-cirrhotic HCC prognosis. 
 Using high-throughput gene expression analysis, we investi-
gated differentially expressed genes in non-cirrhotic HCC tis-
sues. We found AROS to be a unique and significant prognostic 
biomarker for non-cirrhotic HCC, not cirrhosis (data not shown). 
Comparative analysis of AROS mRNA expression between tu-
mor and non-tumoral tissues revealed that AROS is highly ex-
pressed in tumors compared to non-tumors (Fig. 1A) and inter-
estingly, AROS was significantly overexpressed in recurrent tu-
mors compared to non-recurrent ones (Fig. 1B). Stage analysis 
also disclosed higher levels of AROS in tumors across all tumor 
stages and BCLC stages. Additionally, AROS expression increas-
ed with advanced tumor stages, and vascular invasion (Fig. 1C). 
Although AROS expression has not been studied previously in 
tumor versus non-tumor tissues of patients, there is evidence 
supporting our results. AROS is ubiquitously expressed in vari-
ous mouse (15) and human organs but is overexpressed in can-
cer cell lines (16). Since AROS regulates ribosome biogenesis, 
changes to the gene expression for AROS and the resulting re-
duction in ribosome function may contribute to tumor progres-
sion (18, 23-25). In agreement with our speculation, dysregula-
tion of ribosome biogenesis and translation was found to be as-
sociated with breast cancer progression (25). Furthermore, the 
role of AROS as an activator for SIRT1, which is frequently ex-
pressed at later stages of HCC, has been reported (17, 18). In 
addition, we confirmed that AROS is a significant poor prog-
nostic factor for both the short-term and long-term in non-cir-
rhotic HCC (Fig. 2 and Fig. S2). Although we did not investigate 
correlations between AROS and SIRT1 in the current study, these 
results imply that AROS may be related to tumor progression in 
a SIRT1-dependent manner. In agreement with our supposi-
tion, significant overexpression of SIRT1 was observed in HCC 
patients with shorter postoperative survival (26, 27). Collective-
ly, our findings suggest that AROS could be associated with the 
tumor aggressiveness of HCC. To our knowledge, we demon-
Table 1. Correlations of AROS mRNA with clinicopathologic characteristics
Clinicopathologic parameters 
High AROS 
(n = 71)
Low AROS 
(n = 212)
P value
Age ( < 55/ ≥ 55 yr) 43/28 112/100 0.320
Gender (Male/Female) 53/18 166/46 0.624
Hepatitis B infection (n, %) 49 (69.1) 131 (61.8) 0.341
Hepatitis C infection (-/+) 4 (5.6%) 21 (9.9%) 0.392
Tumor stage (I/II/III,IV) 13/30/28 94/83/35 < 0.001*
BCLC stage (A/B/C) 24/31/16 104/88/20 0.007*
AFP level ( > 100 ng/mL, %) 41 (57.7) 84 (39.6) 0.013*
Microvascular invasion (n, %) 57 (80.3) 123 (58.0) 0.001*
Tumor number (multiple, %)) 26 (36.6) 42 (19.8) 0.007*
Tumor size ( > 5 cm, %) 43 (60.6) 96 (45.3) 0.036*
Edmondson grade (I/II/III,IV) 3/60/83 22/152/38 0.087
Portal Vein Invasion (n, %) 16 (22.3) 19 (9.0) 0.005*
*Analyzed by chi square test. BCLC, Barcelona Clinic Liver Cancer; AFP, alpha feto-
protein.
Table 2.  Univariate and multivariate analysis of prognostic factors for 2-yr disease-free survival 
Variables
Univariate analysis Multivariate analysis
HR 95% CI P HR 95% CI P
Age ( < 55 yr/ ≥ 55 yr) 1.11 0.77-1.59 0.574
Gender (male/female) 1.44 0.96-2.14 0.077
Edmondson grade (I, II vs. III, IV) 1.75 1.13-2.70 0.012
HBV (absent vs. present) 1.33 0.91-1.95 0.145
HCV (absent vs. present) 1.46 0.84-2.56 0.181
AFP level ( < 100 ng/mL vs. ≥ 100 ng/mL) 1.91 1.33-2.74 0.000
Tumor size ( ≤ 5 cm vs. > 5 cm) 2.37 1.64-3.44 0.000
Tumor stage (I, II vs. III, IV) 4.38 3.02-6.34 0.000 2.26 1.17-4.36 0.01
Vascular invasion (absent vs. present) 3.83 2.37-6.20 0.000 2.27 1.33-3.87 0.01
Tumor number (single vs. multi) 3.06 2.12-4.43 0.000
AROS (low vs. high) 1.95 1.34-2.83 0.001 1.42 0.95-2.12 0.08
HBV, hepatitis B; HCV, hepatitis C; AFP, alpha fetoprotein.
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strated for the first time that AROS is overexpressed in non-cir-
rhotic HCC, suggesting the potential of AROS as a prognostic 
biomarker.
 In cirrhotic livers, the impact of AROS on carcinogenesis may 
be less than other factors, including the presence of cirrhosis. In 
non-cirrhotic HCC, however, AROS has an important role in 
tumor progression and recurrence. Short-term recurrence and 
long-term recurrence have been considered to have different 
origins and recurrence mechanisms. Considering that short-
term recurrence and long-term recurrence could be affected by 
the primary tumor (unicentric origin) and by surrounding tis-
sue predisposed to neoplastic transformation (multicentric ori-
gin), AROS may affect both processes in non-cirrhotic HCC. In 
this regard, for improved clinical outcomes of the curative-in-
tent treatment in non-cirrhotic HCC, identification of prognos-
tic factors accompanied by new treatment strategies are need-
ed. For instance, non-cirrhotic HCC patients with a high expres-
sion of AROS should be monitored for the short term and could 
be considered for salvage transplantation after surgery. The in-
formation related to AROS expression in non-cirrhotic HCC 
would be important not only for evaluating the mechanism for 
carcinogenesis, but also for improving patients’ survival in par-
ticular. If our findings can be reproduced in a larger cohort, they 
can potentially provide benefits for predicting the prognosis 
and therapeutic strategies to eventually improve the outcome 
of non-cirrhotic HCC.
 Viral infection can trigger hepatic carcinogenesis indepen-
dently of the development of cirrhosis (7, 28). Therefore, in pa-
tients with viral hepatitis, the development of HCC would be 
influenced by the presence of viral hepatitis as well as cirrhosis. 
In the current cohort, HBV-positive HCC was dominant in cir-
rhotic HCC whereas HCV was frequently observed in non-cir-
rhotic HCC (Table S2). These results are different from those of 
a previous comparative analysis between non-cirrhotic and cir-
rhotic HCC in a western institution demonstrating that hepati-
tis C was dominant in cirrhotic HCC (29). However, the inciden-
ces of hepatitis B or C were variable in several studies (7). The 
molecular characteristics would vary according to viral status. 
Regarding AROS expression, we did not observe a significant 
association with the viral status. Further study of the association 
between viral status and AROS expression and validation in 
other cohorts is necessary. However, our results also had some 
drawbacks. Multivariate Cox analysis did not demonstrate the 
significance of AROS as an independent prognostic factor. Con-
sidering that 44.4% of AROS-high patients are in advanced stag-
es (tumor stage III-IV and BCLC C stage), the AROS-high group 
might show poor prognosis in a stage-dependent manner. Al-
though AROS expression is not an independent prognostic fac-
tor, it is strongly related with tumor aggressiveness such as ad-
vanced stage and poor differentiation. Therefore, AROS warrants 
further investigation as a therapeutic target in advanced non-
cirrhotic HCC. In conclusion, AROS is a significant biomarker 
for tumor aggressiveness in non-cirrhotic HCC. 
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Table S1. Sequences of primers and probes
Genes Sequences
AROS F
R
P
CGGAAGACGAAGGCAATTCA
GCCGACTTGGGCACCTTT
CCAGAAACTGCGGAACTCGGCCA
B2M F
R
P
CATTCGGGCCGAGATGTCT
CTCCAGGCCAGAAAGAGAGAGTAG
CCGTGGCCTTAGCTGTGCTCGC
GAPDH F
R
P
CACATGGCCTCCAAGGAGTAA
TGAGGGTCTCTCTCTTCCTCTTGT
CTGGACCACCAGCCCCAGCAAG
HMBS F
R
P
CCAGGGATTTGCCTCACCTT
AAAGAGATGAAGCCCCCACAT
CCTTGATGACTGCCTTGCCTCCTCAG
HPRT1 F
R
P
GCTCGAGATGTGATGAAGGAGAT
CCAGCAGGTCAGCAAAGAATT
CCATCACATTGTAGCCCTCTGTGTGCTC
SDHA F
R
P
CACCTAGTGGCTGGGAGCTT
GCCCAGTTTTATCATCTCACAAGA
TGGCACTTACCTTTGTCCCTTGCTTCA
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Table S2. Comparison of clinicopathological information between cirrhotic HCC and non-cirrhotic HCC
Clinicopathologic parameters Cirrhotic HCC (n = 249) Non-cirrhotic HCC (n = 283) P value
Age ( < 55 / ≥ 55 yr) 150/99 155/128 0.236
Gender (Male/Female) 198/51 219/64 0.624
Hepatitis B infection (n, %) 221 (88.9) 180 (63.6) < 0.001*
Hepatitis C infection (n, %) 10 (4.0) 25 (8.8) 0.042*
Tumor stage (I/II/III, IV) 105/96/48 107/113/63 0.532
BCLC stage (A/B/C) 142/75/32 128/119/36 0.012*
AFP level ( > 100 ng/mL, %) 125 (50.2) 125 (44.1) 0.205
Microvascular invasion (n, %) 141 (56.6) 180 (63.6) 0.109
Tumor number (multiple, %) 58 (23.3) 68 (24.0) 0.923
Tumor size ( ≤ 5 / > 5 cm) 175/74 144/139 < 0.001*
Edmondson grade (I/II/III, IV) 27/169/53 25/21/46 0.195
Portal Vein Invasion (n, %) 32 (12.8) 35 (12.3) 0.971
*Analyzed by chi square test. BCLC, Barcelona Clinic Liver Cancer; AFP, alpha fetoprotein.
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Table S3. Univariate and multivariate analysis of prognostic factors for 5-yr disease-free survival 
Variables
Univariate analysis Multivariate analysis
HR 95% CI P HR 95% CI P
Age ( < 55 yr / ≥ 55 yr) 1.07 0.78-1.46 0.662
Gender (male/female) 1.55 1.10-2.19 0.012
Edmondson grade (I, II vs. III, IV) 1.71 1.15-2.53 0.078
HBV (absent vs. present) 1.29 0.93-1.79 0.131
HCV (absent vs. present) 1.54 0.94-1.42 0.085
AFP level ( < 100 ng/mL vs. ≥ 100 ng/mL) 1.63 1.19-2.23 0.002
Tumor size ( ≤ 5 cm vs. > 5 cm) 1.94 1.42-2.66 0.000
Tumor stage (I, II vs. III, IV) 3.36 2.40-4.71 0.000
Vascular Invasion (absent vs. present) 2.92 2.01-4.24 0.000 2.13 1.40-3.24 0.001
Tumor number (single vs. multi) 2.61 1.87-3.64 0.000
AROS (low vs. high) 1.61 1.15-2.27 0.005 1.21 0.84-1.73 0.309
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Fig. S1. Comparative analysis of AROS mRNA levels in HCC tissues with (recu) or 
without postoperative recurrence (non-recu) within 5 yr. AROS expression was higher 
in recurrent tumors than in non-recurrent tumors exclusively in NonLC.
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Fig. S2. Non-cirrhotic HCC patients with high levels of AROS expression have a shorter DFS for 5 yr. (A) AUC was 0.575. (B) AROS-high group showed significant shorter DFS 
time (P = 0.00495). Thin lines, patients expressed higher levels of AROS (n = 71); broken lines, patients expressed lower levels of AROS (n = 212).
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Fig. S3. Cirrhotic HCC showed no significant difference in prognosis (DFS) between 
AROS-high and AROS-low groups.
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